Grifols vs Organon
GRFS and OGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GRFS and OGN compare
Grifols grew revenue faster over the last twelve months (4.3% versus −3.2% for Organon).
Grifols keeps more of each dollar of sales as profit, with a net margin of 5.3% compared with 3.5% at Organon.
Organon pays a dividend yielding 0.58%; Grifols does not pay one.
Grifols scores higher on the StockData Score (9 against 8 for Organon), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GRFS | OGN |
|---|---|---|
| Size and price | ||
| Market cap | – | $3.7B |
| Share price | $8.80 | $13.90 |
| Change, 1 year | 0.80% | 84.8% |
| Change, 5 years | −25.9% | −55.5% |
| Beta (5Y) | 0.89 | 0.82 |
| Employees | 1,613 | 10K |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 4 (better) | 2 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 18.1× |
| P/S | – | 0.6× |
| P/B | – | 3.1× |
| P/FCF | – | 5.4× |
| FCF yield | – | 18.5% |
| Fair value | – | $15.51 |
| Margin of safety | – | 10.4% |
| Growth | ||
| Revenue growth (TTM) | 4.3% (better) | −3.2% |
| Revenue growth, 5Y average | 7.1% (better) | −0.99% |
| Net income growth (TTM) | 156% (better) | −57.5% |
| EPS growth (TTM) | 157% (better) | −59.9% |
| EPS growth, 5Y average | −8.1% (better) | −39.0% |
| Profitability | ||
| Gross margin | 38.0% | 53.1% (better) |
| Operating margin | 16.5% | – |
| Net margin | 5.3% (better) | 3.5% |
| FCF margin | 10.4% | 11.1% (better) |
| Return on equity | 7.2% | 20.3% (better) |
| Return on invested capital | 14.6% | – |
| Financial health | ||
| Debt / equity | 0.41 (better) | 7.17 |
| Net debt / EBITDA | 0.79 | – |
| Interest coverage | 2.0× | – |
| Current ratio | 2.51 (better) | 2.02 |
| Altman Z-score | – | 1.04 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.58% |
| Payout ratio | 31.8% | 9.4% |
| Years of dividend growth | – | 0 |
| Shareholder yield | – | 0.58% |
| Ownership | ||
| Held by institutions | 20.8% | 83.3% |
| Held by insiders | 0.00% | 0.47% |
| Insider net buying, 12 months | – | −$200K |
| Short interest, % of float | – | 7.5% |
Go deeper
- GRFS stock overview
- GRFS income statement
- GRFS valuation and score
- OGN stock overview
- OGN income statement
- OGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.